Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N.

PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.

2.

MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics.

Xia H, Hui KM.

Cancer Gene Ther. 2012 Nov;19(11):723-30. doi: 10.1038/cgt.2012.58. Epub 2012 Sep 14. Review.

PMID:
22975591
3.

Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives.

Bernhardt M, Galach M, Novak D, Utikal J.

Biotechnol J. 2012 Jun;7(6):810-21. doi: 10.1002/biot.201100347. Epub 2012 May 16. Review.

PMID:
22589234
4.

[Expression of OCT4 protein in bladder cancer and its clinicopathological implications].

Zhao P, Liu C, Xu K, Zheng S, Li H, Xu Y, Xu A, Li B, Huang P.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 May;32(5):643-6. Chinese.

5.

Stem cell interaction with somatic niche may hold the key to fertility restoration in cancer patients.

Bhartiya D, Sriraman K, Parte S.

Obstet Gynecol Int. 2012;2012:921082. doi: 10.1155/2012/921082. Epub 2012 Apr 2.

6.

miR-125b promotes early germ layer specification through Lin28/let-7d and preferential differentiation of mesoderm in human embryonic stem cells.

Wong SS, Ritner C, Ramachandran S, Aurigui J, Pitt C, Chandra P, Ling VB, Yabut O, Bernstein HS.

PLoS One. 2012;7(4):e36121. doi: 10.1371/journal.pone.0036121. Epub 2012 Apr 24.

7.

Umbilical cord blood-derived very small embryonic like stem cells (VSELs) as a source of pluripotent stem cells for regenerative medicine.

Ratajczak MZ, Suszynska M, Pedziwiatr D, Mierzejewska K, Greco NJ.

Pediatr Endocrinol Rev. 2012 Mar;9(3):639-43. Review.

PMID:
22523831
8.

Coexpression of stemness factors Oct4 and Nanog predict liver resection.

Yin X, Li YW, Zhang BH, Ren ZG, Qiu SJ, Yi Y, Fan J.

Ann Surg Oncol. 2012 Sep;19(9):2877-87. doi: 10.1245/s10434-012-2314-6. Epub 2012 Mar 30.

PMID:
22461131
9.

Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis.

He W, Li K, Wang F, Qin YR, Fan QX.

World J Gastroenterol. 2012 Feb 21;18(7):712-9. doi: 10.3748/wjg.v18.i7.712.

10.

Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells.

Chen Z, Wang T, Cai L, Su C, Zhong B, Lei Y, Xiang AP.

J Exp Clin Cancer Res. 2012 Feb 2;31:10. doi: 10.1186/1756-9966-31-10.

11.

Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.

Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ.

PLoS One. 2012;7(1):e29079. doi: 10.1371/journal.pone.0029079. Epub 2012 Jan 17.

12.

ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.

Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC.

Am J Pathol. 2012 Mar;180(3):1159-69. doi: 10.1016/j.ajpath.2011.11.015. Epub 2012 Jan 2. Erratum in: Am J Pathol. 2012 Jul;181(1):374.

PMID:
22222226
13.

Ovarian surface epithelium in patients with severe ovarian infertility: a potential source of cells expressing markers of pluripotent/multipotent stem cells.

Virant-Klun I, Skutella T, Stimpfel M, Sinkovec J.

J Biomed Biotechnol. 2011;2011:381928. doi: 10.1155/2011/381928. Epub 2011 Dec 6.

14.

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

15.

Concise review: Oct4 and more: the reprogramming expressway.

Sterneckert J, Höing S, Schöler HR.

Stem Cells. 2012 Jan;30(1):15-21. doi: 10.1002/stem.765. Review.

16.

Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.

Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P.

Breast Cancer Res. 2011 Sep 27;13(5):R94. doi: 10.1186/bcr3019.

17.

Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours.

Rijlaarsdam MA, van Herk HA, Gillis AJ, Stoop H, Jenster G, Martens J, van Leenders GJ, Dinjens W, Hoogland AM, Timmermans M, Looijenga LH.

Br J Cancer. 2011 Sep 6;105(6):854-63. doi: 10.1038/bjc.2011.270. Epub 2011 Aug 16. Erratum in: Br J Cancer. 2012 Feb 14;106(4):791.

18.

Serous papillary adenocarcinoma possibly related to the presence of primitive oocyte-like cells in the adult ovarian surface epithelium: a case report.

Virant-Klun I, Skutella T, Cvjeticanin B, Stimpfel M, Sinkovec J.

J Ovarian Res. 2011 Aug 9;4:13. doi: 10.1186/1757-2215-4-13.

19.

OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer.

Kim RJ, Nam JS.

Lab Anim Res. 2011 Jun;27(2):147-52. doi: 10.5625/lar.2011.27.2.147. Epub 2011 Jun 22.

20.

Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells.

Hu J, Qin K, Zhang Y, Gong J, Li N, Lv D, Xiang R, Tan X.

Biochem Biophys Res Commun. 2011 Aug 12;411(4):786-91. doi: 10.1016/j.bbrc.2011.07.025. Epub 2011 Jul 21.

PMID:
21798248

Supplemental Content

Support Center